Chemistry:Cligosiban

From HandWiki

Cligosiban (INN; developmental code names IX-01 and PF-3274167) is an oxytocin receptor antagonist which is or was under development for the treatment of premature ejaculation.[1][2][3][4][5] It is taken orally.[1][4] The drug is a small molecule or non-peptide and is a potent, highly selective, and brain-penetrant antagonist of the oxytocin receptor.[3][4] Cligosiban was originated by Pfizer and is under development by Ixchelsis and Chorus Group.[1][2] As of December 2019, it is in phase 2 clinical trials.[1] However, another source lists the drug's development as having been discontinued.[2] The drug failed to show effectiveness in a phase 2b trial.[6]

See also

References

  1. ↑ 1.0 1.1 1.2 1.3 "Cligosiban". 28 December 2019. https://adisinsight.springer.com/drugs/800038534. 
  2. ↑ 2.0 2.1 2.2 "Delving into the Latest Updates on Cligosiban with Synapse". 17 January 2026. https://synapse.patsnap.com/drug/cfa928d6d2c54090860cb5d4594fc542. 
  3. ↑ 3.0 3.1 "Cligosiban, A Novel Brain-Penetrant, Selective Oxytocin Receptor Antagonist, Inhibits Ejaculatory Physiology in Rodents". The Journal of Sexual Medicine 15 (12): 1698–1706. December 2018. doi:10.1016/j.jsxm.2018.10.008. PMID 30527053. 
  4. ↑ 4.0 4.1 4.2 "Pharmacokinetics, Safety, and Tolerability of Single Oral Doses of a Novel Oxytocin Receptor Antagonist-Cligosiban-in Development for Premature Ejaculation: Three Randomized Clinical Trials in Healthy Subjects". The Journal of Sexual Medicine 15 (11): 1547–1557. November 2018. doi:10.1016/j.jsxm.2018.09.006. PMID 30341006. 
  5. ↑ "Pharmacokinetics, Safety, and Tolerability of Multiple Doses of the Novel Oxytocin Receptor Antagonist Cligosiban in Development for Premature Ejaculation: Two Randomized Clinical Trials in Healthy Subjects". The Journal of Sexual Medicine 16 (2): 213–222. February 2019. doi:10.1016/j.jsxm.2018.11.012. PMID 30612858. 
  6. ↑ "The Oxytocin Antagonist Cligosiban Fails to Prolong Intravaginal Ejaculatory Latency in Men with Lifelong Premature Ejaculation: Results of a Randomized, Double-Blind, Placebo-Controlled Phase IIb trial (PEDRIX)". The Journal of Sexual Medicine 16 (8): 1188–1198. August 2019. doi:10.1016/j.jsxm.2019.05.015. PMID 31351660. 



Retrieved from "https://handwiki.org/wiki/index.php?title=Chemistry:Cligosiban&oldid=4243911"